Half-year report · HY
2784.TEDINET S100X0S7
Period2025-04-01 → 2025-09-30
Filed2025-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥1.53T | 2025-04-01 → 2025-09-30 | Cons. | Net sales |
| Revenue | ¥2.96T | 2024-04-01 → 2025-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥1.46T | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Operating income | ¥16.2bn | 2025-04-01 → 2025-09-30 | Cons. | Operating income |
| Operating income | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Ordinary income | ¥17.5bn | 2025-04-01 → 2025-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥40.5bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.3bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥17.9bn | 2025-04-01 → 2025-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥20.7bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥11.5bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥27.4bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥14.1bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥11.6bn | 2025-04-01 → 2025-09-30 | Cons. | Profit loss |
| Net income | ¥13.8bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Total assets | ¥1.50T | at 2025-09-30 | Cons. | Assets |
| Total assets | ¥1.44T | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥1.47T | at 2024-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥1.01T | at 2025-09-30 | Cons. | Liabilities |
| Total liabilities | ¥957.6bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥488.4bn | at 2025-09-30 | Cons. | Net assets |
| Net assets / equity | ¥482.2bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥491.3bn | at 2024-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥175.4bn | at 2025-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥177.1bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥182.7bn | at 2025-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥174.8bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥204.6bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥212.3bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥30.6bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥5.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥15.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥24.9bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥8.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥6.8bn | 2025-04-01 → 2025-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥23.5bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥7.5bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥63.35 | 2025-04-01 → 2025-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥147.54 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥75.26 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 32.5% | at 2025-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 33.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 45
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-04-01 → 2025-09-30 | −¥509m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2025-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2025-09-30 | −¥16.9bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2025-09-30 | ¥147m |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥18.3bn |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥18.3bn |
| Dispensing Pharmacy And Related Businessesreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥156m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥1.37T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥1.36T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥9.8bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥14.8bn |
| Manufacturing Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥25.6bn |
| Manufacturing Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥18.7bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥6.9bn |
| Manufacturing Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | −¥98m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2025-04-01 → 2025-09-30 | ¥135.6bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2025-04-01 → 2025-09-30 | ¥135.3bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥216m |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2025-04-01 → 2025-09-30 | ¥1.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-04-01 → 2025-09-30 | ¥1.55T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-04-01 → 2025-09-30 | ¥1.53T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2025-04-01 → 2025-09-30 | ¥16.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-04-01 → 2025-09-30 | ¥16.6bn |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥18.0bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥18.0bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | ¥174m |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥18.4bn |
| Dispensing Pharmacy And Related Businessesreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥18.4bn |
| Dispensing Pharmacy And Related Businessesreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥248m |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.30T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.29T |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥9.6bn |
| Ethical Pharmaceuticals Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥12.7bn |
| Manufacturing Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥27.0bn |
| Manufacturing Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥18.9bn |
| Manufacturing Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥8.1bn |
| Manufacturing Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥188m |
| Self Medication Products Wholesaling Businessreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥132.4bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥132.1bn |
| Self Medication Products Wholesaling Businessreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥258m |
| Self Medication Products Wholesaling Businessreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥1.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥1.47T |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥1.46T |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥18.0bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥14.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 563
| Item | Context | Value | Unit |
|---|---|---|---|
| Major components of selling general and administrative expenses (text) | InterimDuration | Text · Plus | |
| Reconciliation of ending balance of cash and cash equivalents with account balances per balance sheet (text) | InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | Prior1InterimDuration | Text · Plus | |
| Notes regarding dividend (text) | InterimDuration | Text · Plus | |
| Notes segment information etc type1 semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1InterimDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | InterimDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | InterimDuration | Text · Plus | |
| Notes revenue recognition semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes per share information semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Notes significant events after reporting period semi annual consolidated financial statements (text) | InterimDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | InterimDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |